%0 Journal Article
%A Labrador, Jorge
%A Saiz-Rodríguez, Miriam
%A de Miguel, Dunia
%A de Laiglesia, Almudena
%A Rodríguez-Medina, Carlos
%A Vidriales, María Belén
%A Pérez-Encinas, Manuel
%A Sánchez-Sánchez, María José
%A Cuello, Rebeca
%A Roldán-Pérez, Alicia
%A Vives, Susana
%A Benzo-Callejo, Gonzalo
%A Colorado, Mercedes
%A García-Fortes, María
%A Sayas, María José
%A Olivier, Carmen
%A Recio, Isabel
%A Conde-Royo, Diego
%A Bienert-García, Álvaro
%A Vahi, María
%A Muñoz-García, Carmen
%A Seri-Merino, Cristina
%A Tormo, Mar
%A Vall-Llovera, Ferran
%A Foncillas, María-Ángeles
%A Martínez-Cuadrón, David
%A Sanz, Miguel Ángel
%A Montesinos, Pau
%T Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
%D 2022
%@ 2072-6694
%U http://hdl.handle.net/10668/20882
%X The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56-151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS.
%K acute myeloid leukemia
%K refractory
%K relapsed
%K venetoclax
%~